A double blind, placebo controlled trial of efficacy and safety of oral acyclovir (Zovirax) in the treatment of chickenpox in adults.
A double-blind placebo controlled trial of oral acyclovir in otherwise healthy immune competent young adults with chickenpox was conducted. One hundred males were recruited into the trial, fifty were randomised to receive acyclovir at a dose of 800 mg five times daily for 5 days and fifty to receive matching placebo. Acyclovir recipients experienced itching and required anti-pruritic therapy for a significantly shorter period of time (p less than 0.05); no significant effects of acyclovir therapy on overall rash progression were observed. In patients with a mild rash on entry the maximum daily temperature recorded was significantly lower in the acyclovir group as compared with placebo recipients on day 1 of therapy (p less than 0.01). Acyclovir was extremely well tolerated and no adverse events were reported. Studies with early oral acyclovir therapy in otherwise healthy children with chickenpox has demonstrated significant benefits, particularly in rash progression. It is postulated that the partial benefits shown in this study in adults reflect the high proportion of patients with mild disease and enrollment of the majority of patients more than 24 hours after the rash onset.
Andreoni
M
M
Clinica delle Malattie Infettive, Università degli Studi di Roma Tor Vergata, Italy.
Canfarini
M
M
Grint
P C
PC
Martorelli
M
M
Di Luzio Paparatti
U
U
Rocchi
G
G
D000212:Acyclovir / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D008297:Male
D000212:Acyclovir